A small molecule inhibitor of beta-catenin/CREB-binding protein transcription [corrected].
暂无分享,去创建一个
Hong Ma | Cu Nguyen | Michael Kahn | Masakatsu Eguchi | Randall T Moon | C. Nguyên | J. Teo | M. Eguchi | M. Kahn | R. Moon | Hong Ma | S. Moon | Kwang Won Jeong | Sung Hwan Moon | Jia-Ling Teo | Katayoon H Emami | Dae Hoon Kim | Hak Yeop Kim | Jong Ryul Ha | D. Kim | J. Ha | K. H. Emami | Hakjoong Kim
[1] Michael J. Eck,et al. Structure of a human Tcf4–β-catenin complex , 2001, Nature Structural Biology.
[2] T. Waldman,et al. Proof-of-principle: oncogenic beta-catenin is a valid molecular target for the development of pharmacological inhibitors. , 2002, Molecular cancer therapeutics.
[3] William I. Weis,et al. The Structure of the β-Catenin/E-Cadherin Complex and the Molecular Basis of Diverse Ligand Recognition by β-Catenin , 2001, Cell.
[4] D. Livingston,et al. Gene dose-dependent control of hematopoiesis and hematologic tumor suppression by CBP. , 2000, Genes & development.
[5] Randall T. Moon,et al. The transcriptional coactivator CBP interacts with beta-catenin to activate gene expression. , 2000, The Journal of cell biology.
[6] D. Altieri,et al. Expression of a novel antiapoptosis gene, survivin, correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas. , 1998, Cancer research.
[7] P. Morin,et al. β‐catenin signaling and cancer , 1999 .
[8] S. Minucci,et al. Retinoid receptors in health and disease: co-regulators and the chromatin connection. , 1999, Seminars in cell & developmental biology.
[9] R. Goodman,et al. CBP/p300 in cell growth, transformation, and development. , 2000, Genes & development.
[10] G. Landes,et al. Analysis of human transcriptomes , 1999, Nature Genetics.
[11] C. Hui,et al. Developmentally regulated expression of the transcriptional cofactors/histone acetyltransferases CBP and p300 during mouse embryogenesis. , 1999, The International journal of developmental biology.
[12] Frank McCormick,et al. β-Catenin regulates expression of cyclin D1 in colon carcinoma cells , 1999, Nature.
[13] D. M. Ferkey,et al. Tcf4 can specifically recognize β-catenin using alternative conformations , 2001, Nature Structural Biology.
[14] B. Gumbiner,et al. Adhesion signaling: How β-catenin interacts with its partners , 2001, Current Biology.
[15] H. Clevers,et al. Survivin and molecular pathogenesis of colorectal cancer , 2003, The Lancet.
[16] K. Tanaka,et al. Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[17] F. Pierre,et al. Point: From animal models to prevention of colon cancer. Systematic review of chemoprevention in min mice and choice of the model system. , 2003, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[18] Hans C Clevers,et al. Molecular causes of colon cancer , 2002, European journal of clinical investigation.
[19] A. Sparks,et al. Identification of c-MYC as a target of the APC pathway. , 1998, Science.
[20] Kris Vleminckx,et al. The p300/CBP acetyltransferases function as transcriptional coactivators of β‐catenin in vertebrates , 2000, The EMBO journal.
[21] W. Bodmer,et al. Genetics of colorectal cancer: hereditary aspects and overview of colorectal tumorigenesis. , 2002, British medical bulletin.
[22] D. Altieri,et al. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma , 1997, Nature Medicine.
[23] R. Nusse,et al. Mechanisms of Wnt signaling in development. , 1998, Annual review of cell and developmental biology.
[24] J Diebold,et al. Prognostic significance of survivin expression in diffuse large B-cell lymphomas. , 2000, Blood.
[25] Lin Li,et al. Chromatin immunoprecipitation: a tool for studying histone acetylation and transcription factor binding. , 2003, Methods.
[26] J. Urban,et al. Highly efficient and versatile synthesis of libraries of constrained β-strand mimetics , 1998 .
[27] T. A. Graham,et al. Crystal Structure of a β-Catenin/Tcf Complex , 2000, Cell.
[28] K. Kinzler,et al. Constitutive Transcriptional Activation by a β-Catenin-Tcf Complex in APC−/− Colon Carcinoma , 1997, Science.
[29] J. Behrens,et al. Control of β‐Catenin Signaling in Tumor Development , 2000 .
[30] N. Perrimon,et al. The Promise and Perils of Wnt Signaling Through β-Catenin , 2002, Science.
[31] Jonas Wittwer,et al. Differential role of p300 and CBP acetyltransferase during myogenesis: p300 acts upstream of MyoD and Myf5 , 2003, The EMBO journal.
[32] D. Altieri,et al. Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. , 1998, Cancer research.
[33] R. Fine,et al. A novel stereo-selective sulfonylurea, 1-[1-(4-aminobenzoyl)-2,3-dihydro-1H-indol-6-sulfonyl]-4-phenyl-imidazolidin-2-one, has antitumor efficacy in in vitro and in vivo tumor models. , 2002, Biochemical pharmacology.
[34] J C Reed,et al. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. , 1998, Cancer research.
[35] D. Livingston,et al. p300 Interacts with the Nuclear Proto-Oncoprotein SYT as Part of the Active Control of Cell Adhesion , 2000, Cell.
[36] Frank Petersen,et al. Small-molecule antagonists of the oncogenic Tcf/β-catenin protein complex , 2004 .
[37] C. Albanese,et al. The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[38] D. Altieri,et al. The molecular basis and potential role of survivin in cancer diagnosis and therapy. , 2001, Trends in molecular medicine.
[39] H. Brantjes,et al. TCF: Lady Justice Casting the Final Verdict on the Outcome of Wnt Signalling , 2002, Biological chemistry.